Copyright
©The Author(s) 2020.
World J Cardiol. Nov 26, 2020; 12(11): 559-570
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.559
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.559
Table 1 Baseline characteristics of all studies
Ref. | Damluji et al[12] | Flores-Umanzor et al[13] | Yan et al[15] | Choi et al[14] |
Type of study | Randomized control trial (Post Hoc analysis of BARI-2D) | Cohort (prospective) | Cohort (retrospective) | Cohort (retrospective) |
Country | United States | Spain | China | South Korea |
Period during which study was done | 2001-05 | 2010-14 | 2007-17 | 2003-12 |
Study size (Patients with DM and CTO) | 972 | 538 | 2361 | 702 |
Follow up in months | 60 | 48 | 45 | 46 |
Male (%) | 78 | 82 | 78 | 77 |
Age, mean (yr) | 62.5 | 68.5+/-3.5 | 60 | 64.6 |
Type of stent used if PCI | DES or BMS | - | DES | DES |
Exclusion criteria | Need for immediate revascularization, left main coronary disease, a creatinine level > 2.0 mg/dL, a glycated hemoglobin level > 13.0%, heart failure class III or IV, hepatic dysfunction, or previous PCI or CABG within the last 12 mo | No exclusion criteria | (1) Patients who had a history of CABG; (2) Patients who had acute myocardial infarction (MI) due to non-CTO vessels 1 mo before the study; (3) Patients who had left main coronary artery disease; and (4) Patients who had histories of cancer or other diseases that could confuse the end points | History of previous CABG; history of cardiogenic shock or cardiopulmonary resuscitation; ST-segment elevation acute MI during the preceding 48 h |
Quality score2 | 7 | 5 | 5 | 5 |
Table 2 Percentage prevalence of co-morbidities across studies (actual prevalence in brackets)
Ref. | Damluji et al[12] | 1Flores-Umanzor et al[13] | Yan et al[15] | Choi et al[14] | |||||
OMT (n = 490) | ER (n = 482) | OMT (n = 326) | ER | ER | OMT (n = 118) | ER (n = 118) | OMT (n = 318) | ER (n = 384) | |
PCI (n = 76) | CABG (n = 136) | ||||||||
HTN | 80 (385) | 81 (387) | 85 (276) | 82 ( 62) | 86 (117) | 66.9 (79) | 71.2 (84) | 70.7 (225) | 70.3 (270) |
Previous MI | 44 (214) | 41 (197) | 33 (108) | 28 (21) | 28 (21) | 56.8 (67) | 55.9 (66) | 34.9 (111) | 18.0 (69) |
Prior CHF | 7 (36) | 9 (43) | - | - | - | 14.4 (17) | 10.2 (12) | - | - |
Prior Stent/PCI | 11 (56) | 12 (59) | - | - | - | 48.3 (57) | 42.4 (50) | 30.5 (97) | 22.1 (85) |
Prior CVA/TIA | 10 (49) | 10 (46) | - | - | - | 5.1 (6) | 5.9 (7) | 12.3 (39) | 11.2 (43) |
Prior Revascularizatio | 31 (151) | 26 (124) | - | - | - | - | - | - | - |
Prevnious CABG | - | - | 14 (45) | 5 (4) | 4 (5) | - | - | 0 | 0 |
HbA1c mean | 7.4 | 7.3 | 7.6 ± 0.1 | 7.6 ± 0.2 | 7.3 ± 0.1 | - | - | - | - |
Dyslipidemia | 83 (402) | 84 (400) | 75 (246) | 71 (54) | 74 (100) | 51.7 (61) | 50 (59) | 21.7 (69) | 31.3 (120) |
Smoking | - | - | 52 (169) | 55 (42) | 59 (80) | 55.9 (66) | 57.6 (68) | 28.6 (91) | 32.8 (126) |
Peripheral vascular disease | - | - | 45 (145) | 33 (25) | 35 (47) | 3.4 (4) | 3.4 (4) | 6.0 (19) | 3.4 (13) |
Table 3 Chronic total occlusions location with number of chronic total occlusions lesions among studies in percentages (actual prevalence in brackets)
Ref. | Damluji et al[12] | Flores-Umanzor et al[13] | Yan et al[15] | Choi et al[14] | ||||
OMT | ER | OMT (n = 326) | ER (n = 212) | OMT (n = 118) | ER (n = 118) | OMT (n = 318) | ER (n = 384) | |
Number of CTO lesions | ||||||||
1 | - | - | 80 (261) | 75 (159) | - | - | ||
2 | - | - | 79 (60) | 24 (50) | - | - | ||
3 | - | - | 1.5 (5) | 1.4 (3) | - | - | ||
CTO location | ||||||||
LAD artery | - | - | 18 (60) | 24 (51) | 30.5 (36) | 28.0 (33) | 26.4 (84) | 38.5 (148) |
LCX artery | - | - | 19 (62) | 20 (42) | 28.0 (33) | 26.3 (31) | 36.5 (116) | 29.2 (112) |
RCA | - | - | 52 (170) | 47 (100) | 41.5 (49) | 45.8 (54) | 56.3 (117) | 47.9 (184) |
Other coronary artery branches | - | - | 10 (34) | 9 (19) | - | - | - | - |
- Citation: Khan MS, Sami FA, Singh H, Ullah W, Al-Dabbas M, Changal KH, Mir T, Ali Z, Kabour A. Medical therapy vs early revascularization in diabetics with chronic total occlusions: A meta-analysis and systematic review. World J Cardiol 2020; 12(11): 559-570
- URL: https://www.wjgnet.com/1949-8462/full/v12/i11/559.htm
- DOI: https://dx.doi.org/10.4330/wjc.v12.i11.559